Novel Approaches to Chronic Conditions
Edesa is exploring new ways to treat dermatological and gastrointestinal diseases, including innovative alternatives to topical steroids, which can have serious side-effects.
Clinical Pipeline Status
As of December 1, 2019
Our current clinical studies are designed to further evaluate the safety and efficacy of our sPLA2 inhibitor technology. Since these clinical-ready drug candidates come to us with well characterized efficacy and safety data, we avoid much of the lengthy process of preclinical R&D studies and advance to meaningful data readouts more quickly.
Allergic Contact Dermatitis
EB01 is a novel sPLA2 inhibitor for the topical treatment of chronic Allergic Contact Dermatitis (ACD). EB01 employs a novel mechanism of action and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in contact dermatitis patients.
Contact dermatitis is one of the most common occupational health illnesses in the United States, and has been estimated to cost approximately $2 billion annually. We estimate that there are more than 13.2 million people in the United States with contact dermatitis, with between 20% and 60% of all cases of contact dermatitis diagnosed as ACD. We believe EB01 will primarily benefit those who have chronic ACD.
Edesa is in the early stages of conducting a double-blind, dose-ranging vehicle-controlled adaptive design clinical trial to evaluate the safety and efficacy of EB01 in a population with moderate to severe allergic contact dermatitis
Additional Dermatological Indications
sPLA2 Inhibitor and Others
Edesa also intends to expand the utility of its sPLA2 inhibitor technology across multiple indications, which could include acne or other inflammatory disorders. We are also in discussions to expand our portfolio with assets to treat other serious skin conditions.
EB02 is a novel sPLA2 inhibitor for the treatment of hemorrhoids.
Hemorrhoids affect ~12.5 million adults in the US. Each year 3 million prescriptions are written in the U.S. for hemorrhoids, in addition to 22 million over the counter units. Current treatments entered the market prior to 1962 and provide only temporary relief from symptoms.
Edesa is planning to evaluate EB02 in a proof-of-concept study to aid in the design of subsequent clinical studies needed for approval.
Anal Fissures and Additional GI Indications
Anal fissure affect 2-3% of adults in the US. Treatments start with diet modification, stool softeners and steroids, and may include surgery.
In-licensed. We are also in discussions to expand our portfolio with assets to treat other serious gastrointestinal conditions.
We believe that targeting the sPLA2 enzyme family with enzyme inhibitors will have a superior therapeutic effect because the inflammatory process will be inhibited at its inception rather than after inflammation has occurred.